A phase IV, single centre, open-label study to investigate the kinetics of the B cell response to the C saccharide component of Chiron's meningococcal C conjugate vaccine administered to healthy children at least 12 months of age after priming with a commercially available men ACWY conjugate vaccine [meningococcal vaccine groups A C Y W-135 conjugate] at 2, 3 and 4 months of age.

Trial Profile

A phase IV, single centre, open-label study to investigate the kinetics of the B cell response to the C saccharide component of Chiron's meningococcal C conjugate vaccine administered to healthy children at least 12 months of age after priming with a commercially available men ACWY conjugate vaccine [meningococcal vaccine groups A C Y W-135 conjugate] at 2, 3 and 4 months of age.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2014

At a glance

  • Drugs Meningococcal vaccine group C conjugate (Primary)
  • Indications Meningococcal group C infections
  • Focus Pharmacodynamics
  • Sponsors Chiron Corporation; Novartis
  • Most Recent Events

    • 15 Nov 2011 Actual end date (Aug 2006) added as reported by ClinicalTrials.gov.
    • 04 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top